Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.05) EPS for the quarter, FiscalAI reports. The firm had revenue of $7.87 million during the quarter.
Lakefront Biotherapeutics American Depositary Shares Trading Down 0.5%
Shares of NASDAQ LKFT traded down $0.17 during mid-day trading on Friday, reaching $33.76. 184,976 shares of the company’s stock were exchanged, compared to its average volume of 199,870. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -23.94 and a beta of 0.22. The business has a fifty day simple moving average of $30.26 and a 200 day simple moving average of $29.94. Lakefront Biotherapeutics American Depositary Shares has a twelve month low of $25.68 and a twelve month high of $36.24.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the stock. Alps Advisors Inc. bought a new position in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter worth about $2,617,000. ABC Arbitrage SA acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 1st quarter worth about $382,000. Commonwealth Equity Services LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at approximately $279,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the first quarter valued at approximately $248,000. Institutional investors own 32.46% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently weighed in on LKFT. Royal Bank Of Canada raised shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $26.00 to $45.00 in a research note on Wednesday, September 23rd. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, October 2nd. TD Cowen began coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, August 21st. They issued a “buy” rating for the company. UBS Group upgraded shares of Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a report on Wednesday, September 23rd. Finally, Morgan Stanley initiated coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, October 20th. They set an “equal weight” rating and a $26.00 price target on the stock. Three research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $35.50.
View Our Latest Analysis on LKFT
About Lakefront Biotherapeutics American Depositary Shares
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Lakefront Biotherapeutics American Depositary Shares
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
